The epidemiology of multiple sclerosis. insights to disease pathogenesis.

Handbook of Clinical Neurology

Volumn 122, Issue , 2014, Pages 231-266

  Goodin, Douglas S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical; EBV; Epidemiology; Epstein Barr virus; Gender; Genetics; Incidence; Infection; Mortality; MS; Multiple sclerosis; Natural history; Pathogenesis; Presentation; Prevalence; Sex; Smoking; Stress; Susceptibility; Trauma; Vitamin D

Indexed keywords

VITAMIN D;

ANIMAL; ARTICLE; CLINICAL; DISEASE MODEL; EPIDEMIOLOGY; EPSTEIN BARR VIRUS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENDER; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HISTORY; HUMAN; IMMUNOLOGY; INCIDENCE; INFECTION; INJURY; MORTALITY; MULTIPLE SCLEROSIS; PATHOGENESIS; PRESENTATION; PREVALENCE; PROGNOSIS; RISK FACTOR; SEX; SMOKING; STRESS; SUSCEPTIBILITY;

CLINICAL; EBV; EPIDEMIOLOGY; EPSTEIN BARR VIRUS; GENDER; GENETICS; INCIDENCE; INFECTION; MORTALITY; MS; MULTIPLE SCLEROSIS; NATURAL HISTORY; PATHOGENESIS; PRESENTATION; PREVALENCE; SEX; SMOKING; STRESS; SUSCEPTIBILITY; TRAUMA; VITAMIN D;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE-ENVIRONMENT INTERACTION; HUMANS; MULTIPLE SCLEROSIS; PROGNOSIS; RISK FACTORS;

EID: 84893441857     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52001-2.00010-8     Document Type: Chapter

References (231)

1. Ackerman K. Relationship between multiple sclerosis exacerbations and stress. Psychosom. Med. 2004, 66:288-289.
2. Ackerman K.D., Heyman R., Rabin B.S., et al. Stressful life events precede exacerbations of multiple sclerosis. Psychosom. Med. 2002, 64:916-920.
3. Ackerman K.D., Stover A., Heyman R., et al. Relationship of cardiovascular reactivity, stressful life events, and multiple sclerosis disease activity. Brain Behav. Immun. 2003, 17:141-151.
4. Adams C.W.M. A colour atlas of multiple sclerosis and other myelin disorders 1989, 101. Wolfe Medical Publications, Ipswich, Suffolk.
5. Alotaibi S., Kennedy J., Tellier R., et al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004, 291:1875-1879.
6. Alter M., Yamoor M., Harshe M. Multiple sclerosis and nutrition. Arch. Neurol. 1974, 31:267-272.
7. Alter M., Kahana E., Loewenson R. Migration and risk of multiple sclerosis. Neurology 1978, 28:1089-1093.
8. Amato M.P., Fratiglioni L., Groppi C., et al. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch. Neurol. 1988, 45:746-748.
9. Andersen O., Lygner P.E., Bergstrom T., et al. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J. Neurol. 1993, 240:417-422.
10. Antonovsky A., Leibowitz U., Smith H.A., et al. Epidemiological study of multiple sclerosis in Israel. I. An overall review of methods and findings. Arch. Neurol. 1965, 13:183-193.
11. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann. Neurol. 2007, 61:288-299.
12. Ascherio A., Munger K.L., Lennette E.T., et al. Epstein-Barr virus antibodies and the risk of multiple sclerosis: A prospective study. Am. Med. Assoc. J. 2001, 286:3083-3088.
13. Bager P., Nielsen N.M., Bihrmann K., et al. Sibship characteristics and risk of multiple sclerosis: A nationwide cohort study in Denmark. Am. J. Epidemiol. 2006, 163:1112-1117.
14. Bagos P.G., Nikolopoulos, Ioannidid A. Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis. Mult. Scler. 2006, 12:397-411.
15. Bangsi D., Ghadirian P., Ducic S., et al. Dental amalgam and multiple sclerosis: a case-control study in Montreal, Canada. Int. J. Epidemiol. 1998, 27:667-671.
16. Barnett M.H., William D.B., Day S., et al. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J. Neurol. Sci. 2003, 213:1-6.
17. Bar-Or A., Oliviera E.M.L., Anderson D.E., et al. Molecular pathogenesis of multiple sclerosis. J. Neuroimmunol. 1999, 100:252-259.
18. Bartolomei M.S., Tilghman S.M. Genomic imprinting in mammals. Annu. Rev. Genet. 1997, 31:493-525.
19. Bø L., Vedeler C.A., Nyland H.I., et al. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 2003, 62:723-732.
20. Bodnar L.M., Simhan H.N., Powers R.W., et al. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J. Nutr. 2007, 137:447-452.
21. Brain R., Wilkinson M. The association of cervical spondylosis and disseminated sclerosis. Brain 1957, 80:456-478.
22. Bray P.F., Bloomer L.C., Salmon V.C., et al. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch. Neurol. 1983, 40:406-408.
23. Brønnum-Hansen H., Koch-Henriksen N., Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004, 127:844-850.
24. Bruder C.E.G., Piotrowski A., Gijsbers A.C.J., et al. Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am. J. Hum. Genet. 2008, 82:763-771.
25. Buljevac D., Hop W.C.J., Reedeker W., et al. Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. Br. Med. J. 2003, 327:646-651.
26. Cabre P., Signate A., Olindo S., et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 2005, 128:2899-2910.
27. Cantorna M.T. Vitamin D, and autoimmunity: Is vitamin D status an environmental factor affecting autoimmune disease prevalence?. Proc. Soc. Exp. Biol. Med. 2000, 223:230-233.
28. Cantorna M.T., Mahon B.D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp. Biol. Med. 2004, 229:1136-1142.
29. Casetta I., Invernizzi M., Granieri E. Multiple sclerosis and dental amalgam: case-control study in Ferrara, Italy. Neuroepidemiology 2001, 20:134-137.
30. Celius E.G., Vandvik B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur. J. Neurol. 2001, 8:463-469.
31. Chaudhuri M.D., Behan P.O. Acute cervical hyperextention-hyperflexion injury may precipitate and/or exacerbate symptomatic multiple sclerosis. Eur. J. Neurol. 2001, 8:659-664.
32. Chiappa K.H. Pattern shift visual, brainstem auditory, and short latency somatosensory evoked potentials in multiple sclerosis. Neurology 1980, 30:110-123.
33. Cohen R.A., Kessler H.R., Fischer M. The expanded disability status scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis. J. Neurol. Sci. 1993, 115:132-135.
34. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
35. Compston A., Confavreux C., Lassmann H., et al. McAlpine's multiple sclerosis 2006, Churchill Livingstone, London. 4th edn.
36. Confavreux C., Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606-616.
37. Confavreux C., Hutchinson M., Hours M.M., et al. Rate of pregnancy-related relapse in multiple sclerosis. N. Engl. J. Med. 1998, 339:285-291.
38. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126:770-782.
39. Conlon P., Oksenberg J.R., Zhang J. The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system. Neurobiol. Dis. 1999, 6:149-166.
40. Craelius W. Comparative epidemiology of multiple sclerosis and dental caries. J. Epidemiol. Community Health 1978, 32:155-165.
41. Da Silva K.R.P., Papais R.P., Fernandez y Fernandez O., et al. Potenciais fatores de risco para o desenvolvimento de esclerose multipla no Rio de Janeiro: um estudo caso controle. Arq. Neuropsiquiatr. 2009, 67:229-234.
42. Dalton C.M., Brex P.A., Miszkiel K.A., et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann. Neurol. 2002, 52:47-53.
43. De Jager P.L., Jia X., Wang J., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 2009, 41:776-782.
44. Dean G., Kurtzke J.F. On the risk of multiple sclerosis according to age at immigration to South Africa. Br. Med. J. 1971, 3:725-729.
45. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J. 2001, 15:2579-2585.
46. Dyment D.A., Herrera B.M., Cader Z., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum. Mol. Genet. 2005, 14:2019-2026.
47. Dyment D.A., Yee I.M.L., Ebers G.C., et al. Multiple sclerosis in stepsiblings: Recurrence risk and ascertainment. J. Neurol. Neurosurg. Psychiatry 2006, 77:258-259.
48. Ebers G. Multiple sclerosis, stress and the rules of evidence. Practical Neurol. 2004, 4:66-69.
49. Ebers G.C., Sadovnick A.D., Risch N.J., et al. A genetic basis for familial aggregation in multiple sclerosis. Nature 1995, 377:150-151.
50. Ebers G.C., Yee I.M.L., Sandovnick A.D., et al. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Ann. Neurol. 2000, 48:927-931.
51. Ebers G.C., Sadovnick A.D., Dyment D.A., et al. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 2004, 363:1773-1774.
52. Edwards S., Zvartau M., Clarke H., et al. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1998, 64:736-741.
53. Elian M., Nightingale S., Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa, and the West Indies. J. Neurol. Neurosurg. Psychiatry 1990, 53:906-911.
54. Emmons K.M., Colditz G.A. Preventing excess sun exposure: It is time for a national policy. J. Natl. Cancer Inst. 1999, 91:1269-1270.
55. Engell T. A clinical patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol. Scand. 1989, 79:428-430.
56. 3 on cytokine production by human decidual cells. Biol. Reprod. 2006, 75:816-822.
57. Farrell P.J. Role for HLA in susceptibility to infectious mononucleosis. J. Clin. Invest. 2007, 117:2756-2758.
58. Ferguson B., Matyszak M.K., Esiri M.M., et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120:393-399.
59. Filippi M., Rocca M.A., Martino G., et al. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann. Neurol. 1998, 43:809-814.
60. Fisniku L.K., Brex P.A., Altmann D.R., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
61. Fitzgerald G., Harbige L.S., Forti A., et al. The effect of nutritional counceling on diet and plasma EFA status in multiple sclerosis patients over 3 years. Hum. Nutr. Appl. Nutr. 1987, 41A:297-310.
62. Fraga M.F., Ballestar E., Paz M.F., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:10604-10609.
63. Francis D.A., Bain P., Swan A.V., et al. An assessment of disability scales used in multiple sclerosis. Arch. Neurol. 1991, 48:299-301.
64. Freedman D.M., Mustafa M., Alavanja M.C.R. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup. Environ. Med. 2000, 57:418-421.
65. French Research Group on Multiple Sclerosis Multiple sclerosis in 54 twinships: concordance rate is independent of zygosity. Ann. Neurol. 1992, 32:724-727.
66. Frohman E.M., Goodin D.S., Calabresi P.A., et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003, 61:602-611.
67. Gadoth N. Review article: multiple sclerosis in children. Brain Dev. 2003, 25:229-232.
68. Georgi V.W. Multiple Sklerose: Pathologisch-Anamtomische Befunde multiple Sklerose bei klinisch nicht diagniostizierte Krankbeiten. Schweiz. Med. Wochenschr. 1966, 20:605-607.
69. Ghadirian P., Jain M., Ducic S., et al. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int. J. Epidemiol. 1998, 27:845-852.
70. Gilbert J., Sadler M. Unsuspected multiple sclerosis. Arch. Neurol. 1983, 40:533-536.
71. Gillie O. A new government policy is needed for sunlight and vitamin D. Br. J. Dermatol. 2006, 154:1052-1061.
72. Golan D., Somer E., Dishon S., et al. The impact of exposure to war stress on exacerbations of multiple sclerosis. Ann. Neurol. 2008, 64:143-149.
73. Goldacre M.J., Wotton C.J., Seagroatt V., et al. Multiple sclerosis after infectious mononucleosis: record linkage study. J. Epidemiol. Community Health 2004, 58:1032-1035.
74. Goldacre M.J., Abisgold J.D., Yeates D.G.R., et al. Risk of multiple sclerosis after head injury: record linkage study. J. Neurol. Neurosurg. Psychiatry 2006, 77:351-353.
75. Goodin D.S. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 1999, 18:53-63.
76. Goodin D.S. Relationship between multiple sclerosis exacerbations and stress. Psychosom. Med. 2004, 66:287-288.
77. Goodin D.S. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?. Ann. Neurol. 2006, 59:597-605.
78. Goodin D.S. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 2009, 4:e4565.
79. Goodin D.S. The genetic basis of multiple sclerosis: a model for MS susceptibility. BMC Neurol. 2010, 10:101.
80. Goodin D.S. The genetic and environmental bases of complex human-disease: extending the utility of twin-studies. PLoS One 2012, 7:e47875.
81. Goodin D.S., Ebers G.C., Johnson K.P., et al. The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1999, 52:1737-1745.
82. Goodin D.S., Jones J., Li D., et al. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One 2011, 6:e22444.
83. Goodin D.S., Reder A.T., Ebers G.C., et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012, 78:1315-1322.
84. Goodkin D.E., Rooney W.D., Sloan R., et al. A serial study of new MS lesions and the white matter from which they arise. Neurology 1998, 51:1689-1697.
85. Griffin M.D., Lutz W., Phan V.A., et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. 2001, 98:6800-6805.
86. Grønlie S.A., Myrvoll E., Hansen G., et al. Multiple sclerosis in North Norway, and first appearance in an indigenous population. J. Neurol. 2000, 247:129-133.
87. Gronseth G.S., Ashman E.J. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1720.
88. Haahr S., Plesner A.M., Vestergaard B.F., et al. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol. Scand. 2004, 109:270-275.
89. Hafler D.A., Compston A., Sawcer S., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357:851-862.
90. Hansen T., Skytthe A., Stenager E., et al. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult. Scler. 2005, 11:504-510.
91. Harel-Meir M., Sherer Y., Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases. Nat. Clin. Pract. Rheumatol. 2007, 3:707-715.
92. Hawkins S.A., McDonnell G.V. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J. Neurol. Neurosurg. Psychiatry 1999, 67:148-152.
93. Hayes C.E., Nashold F.E., Spach K.M., et al. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. 2003, 49:277-300.
94. Heaney R.P., Davies K.M., Chen T.C., et al. Human surum 25-hydrocholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 2003, 77:204-210.
95. Henle W., Henle G., Andersson J., et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:570-574.
96. Hernán M.A., Olek M.J., Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999, 53:1711-1718.
97. Hernán M.A., Olek M.J., Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am. J. Epidemiol. 2001, 154:69-74.
98. Hernán M.A., Jick S.S., Logroscino G., et al. Cigarette smoking and the progression of multiple sclerosis. Brain 2005, 128:1461-1465.
99. Herrera B.M., Ramagopalan S.V., Orton S., et al. Parental transmission of MS in a population-based Canadian cohort. Neurology 2007, 69:1208-1212.
100. Hirst C., Swingler R., Compston D.A., et al. Survival and cause of death in multiple sclerosis: a prospective population-based study. J. Neurol. Neurosurg. Psychiatry 2008, 79:1016-1021.
101. Holick M.F. Vitamin D, requirements for humans of all ages: new increased requirements for women and men 50 years and older. Osteoporos. Int. 1998, 8(Suppl 2):S24-S29.
102. Houtchens M.K. Pregnancy and multiple sclerosis. Semin. Neurol. 2007, 27:434-441.
103. Huggins H.A. Medical implications of dental mercury: A review. Explore (NY) 2007, 3:110-117.
104. Huggins H.A., Levy T.E. Multiple sclerosis after dental amalgam removal. Altern. Med. Rev. 1998, 3:295-300.
105. Ingalls T.H. Epidemiology, etiology, and prevention of multiple sclerosis. Hypothesis and fact. Am. J. Forensic Med. Pathol. 1983, 4:55-61.
106. Islam T., Gauderman W.J., Cozen W., et al. Differential twin concordance for multiple sclerosis by latitude of birthplace. Ann. Neurol. 2006, 60:56-64.
107. Jablonski N.G., Chaplin G. The evolution of human skin coloration. J. Hum. Evol. 2000, 39:57-106.
108. Jablonski N.G., Chaplin G. Skin deep. Sci. Am. 2002, 287:74-81.
109. Kahana E., Zilber N., Abramson J.H., et al. Multiple sclerosis: Genetic versus environmental aetiology: epidemiology in Israel updated. J. Neurol. 1994, 241:341-346.
110. Kantarci O.H., Barcellos L.F., Atkinson E.J., et al. Men transmit MS more often to their children vs women: The Carter effect. Neurology 2006, 67:305-310.
111. Kappos L., Freedman M.S., Polman C.H., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007, 370:389-397.
112. Kaufman M., Gaydos C.A., Sriram S., et al. Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult. Scler. 2002, 8:289-294.
113. Kimball S.M., Ursell D., O'Connor P., et al. Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 2007, 86:645-651.
114. Kimlin M.G., Olds W.J., Moore M.R. Location and vitamin D synthesis: is the hypothesis validated by geophysical data?. J. Photochem. Photobiol. B 2007, 86:234-239.
115. Kip K.E., Cohen F., Cole S.R., et al. Recall bias in a prospective cohort study of acute time-varying exposures: example from the herpetic eye disease study. J. Clin. Epidemiol. 2001, 54:482-487.
116. Koch-Henderson N. Multiple sclerosis in Scandinavia and Finland. Acta Neurol. Scand. 1995, 161:55-59.
117. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult. Scler. 1999, 5:293-296.
118. Kremenchutsky M., Rice G.P.A., Baskerville D.M., et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006, 129:584-594.
119. Kroencke D.C., Denney D.R. Stress and coping in multiple sclerosis: exacerbation, remission and chronic subgroups. Mult. Scler. 1999, 5:89-93.
120. Krone B., Pohl D., Rostasy K., et al. Common infectious agents in multiple sclerosis: a case-control study in children. Mult. Scler. 2008, 14:136-139.
121. Kurtzke J.F. A new scale for evaluating disability in multiple sclerosis. Neurology 1955, 5:580-583.
122. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
123. Kuusisto H., Kaprio J., Kinnunen E., et al. Concordance and heritability of multiple sclerosis in Finland: Study on a nationwide series of twins. Eur. J. Neurol. 2008, 15:1106-1110.
124. Larsen P.D., Bloomer L.C., Bray P.F. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985, 35:435-438.
125. Levin L.I., Munger K.L., Rubertone M.V., et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. Am Med Assoc J 2005, 293:2496-2500.
126. Li J., Johansen C., Brønnum-Hansen H., et al. The risk of multiuple sclerosis in bereaved parents: a nationwide cohort study in Denmark. Neurology 2004, 62:726-729.
127. Liguori M., Marrosu M.G., Pugliatti M., et al. Age at onset in multiple sclerosis. Neurol. Sci. 2000, 21:S825-S829.
128. Lips P. Vitamin D, physiology. Prog. Biophys. Mol. Biol. 2006, 92:4-8.
129. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis. Neurology 1996, 46:907-911.
130. McGrother C.W., Dugmore C., Phillips M.J., et al. Multiple sclerosis, dental caries and fillings: a case-control study. Br. Dent. J. 1999, 187:261-264.
131. McGuigan C., Dunne C., Crowley J., et al. Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland. J. Neurol. 2005, 252:1245-1248.
132. McIntosh A.M., Holmes S., Gleeson S., et al. Maternal recall bias, obstetric history and schizophrenia. Br. J. Psychiatry 2002, 181:520-525.
133. Merelli E., Casoni F. Prognostic factors in multiple sclerosis: role of intercurrent infections and vaccinations against influenza and hepatitis B. Neurol. Sci. 2000, 21:S853-S856.
134. Mikaeloff Y., Caridade G., Tardieu M., et al. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 2007, 130:2589-2595.
135. Mohr D.C., Goodkin D.E., Bacchetti P., et al. Psychological stress and the subsequent appearance of new brain lesions in MS. Neurology 2003, 55:55-61.
136. Montgomery S.M., Bahmanyar S., Hillert J., et al. Maternal smoking during pregnancy and multiple sclerosis amongst offspring. Eur. J. Neurol. 2008, 15:1398-1402.
137. Moses H., Sriram S. An infectious basis for multiple sclerosis: perspectives on the role of Chlamydia pneumoniae and other agents. BioDrugs 2001, 15:199-206.
138. Müller A.M.S., Ihorst G., Mertelsmann R., et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann. Hematol. 2005, 84:1-12.
139. Mumford C.J., Wood N.W., Kellar-Wood H., et al. The British Isles survey of multiple sclerosis in twins. Neurology 1994, 44:11-15.
140. Munch M., Riisom K., Christensen T., et al. The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients?. Acta Neurol. Scand. 1998, 97:171-174.
141. Munger K.L., DeLorenze G.N., Levin L.I., et al. A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts. Neurology 2004, 62:1799-1803.
142. Munger K.L., Zhang S.M., O'Reilly E., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
143. Munger K.L., Levin L.I., Hollis B.W., et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. Am. Med. Assoc. J. 2006, 296:2832-2838.
144. Murry T.J. The history of multiple sclerosis. Multiple sclerosis: diagnosis, medical management, and rehabilitation 2000, 1-35. Demos Medical Publishing, New York. J.S. Burks, K.P. Johnson (Eds.).
145. Myhr K.M., Riise T., Barrett-Connor E., et al. Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway. J. Neurol. Neurosurg. Psychiatry 1998, 64:539-542.
146. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 2005, 26:662-687.
147. Nielsen N.M., Westergaard T., Rostgaard K., et al. Familial risk of multiple sclerosis: a nationwide cohort study. Am. J. Epidemiol. 2005, 162:774-778.
148. Nielsen T.R., Rostgaard K., Nielsen N.M., et al. Multiple sclerosis after infectious mononucleosis. Arch. Neurol. 2007, 64:72-75.
149. Nisipeanu P., Korczyn A.D. Psychological stress as risk factor for exacerbations in multiple sclerosis. Neurology 1993, 43:1311-1312.
150. Noseworthy J.H., Vandervort M.K., Wong C.J., et al. Canadian Cooperative MS Study Group. Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 1990, 40:971-975.
151. O'Riordan J.I., Thompson D.P., Kingsley D.P., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998, 121:495-503.
152. Okuda D.T., Mowry E.M., Beheshtian A., et al. Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome. Neurology 2009, 72:800-805.
153. Oppenheimer D.R. The cervical cord in multiple sclerosis. Neuropathol. Appl. Neurobiol. 1978, 4:151-162.
154. Optic Neuritis Study Group Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch. Neurol. 2008, 65:727-732.
155. Orton S.M., Herrera B.M., Yee I.M., et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006, 5:932-936.
156. Padyukov L., Silva C., Stolt P., et al. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004, 50:3085-3092.
157. Panitch H.S. Influence of infection on exacerbations of multiple sclerosis. Ann. Neurol. 1994, 36:S25-S28.
158. Parratt J., Tavendale R., O'Riordan J., et al. Chlamydia pneumoniae-specific serum immune complexes in patients with multiple sclerosis. Mult. Scler. 2008, 14:292-299.
159. Peterson J.W., Bø L., Mørk S., et al. Transected neurites, apoptotic neurons and reduced inflammation in cortical MS lesions. Ann. Neurol. 2001, 50:389-400.
160. Pittock S.J., Mayr W.T., McClelland R.L., et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004, 62:601-606.
161. Pohl D., Krone B., Rostasy K., et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006, 67:2063-2065.
162. Polman C.H., Reingold S.C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2010, 69:292-302.
163. Ponsonby A.L., van der Mei, Dwyer T., et al. Exposure to infant siblings during early life and risk of multiple sclerosis. Am. Med. Assoc. J. 2005, 293:463-469.
164. Poser C.M. The role of trauma in the pathogenesis of multiple sclerosis: a review. Clin. Neurol. Neurosurg. 1994, 96:103-110.
165. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
166. Potagas C., Mitsonis C., Watier L., et al. Influence of anxiety and reported stressful life events on relapses in multiple sclerosis: a prospective study. Mult. Scler. 2008, 14:1262-1268.
167. Ramagopalan S.V., Anderson C., Sadovnick A.D., et al. Genomewide study of multiple sclerosis. N. Engl. J. Med. 2007, 357:2199-2200.
168. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009, 5:e1000369.
169. Ranzato F., Perini P., Tzintzeva E., et al. Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey. Mult. Scler. 2003, 9:387-392.
170. Riise T., Nortvedt M.W., Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 2003, 61:1122-1124.
171. Ristori G., Cannoni S., Stazi M.A., et al. Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study. Ann. Neurol. 2006, 59:27-34.
172. Robertson N.P., Fraser M., Deans J., et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 1996, 119:449-455.
173. Rodríguez Regal A., del Campo Amigo M., Paz-Esquete J., et al. Estudio de casos y controles sobre la influencia del hábito tabáquico en la esclerosis multiple. Neurologia 2009, 24:177-180.
174. Rodriguez M., Siva A., Cross S., et al. Optic neuritis: a population based study in Olmsted county, Minnesota. Neurology 1994, 44:A374.
175. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 2001, 22:117-139.
176. Rosenbaum P.R., Rubin D.B. The central role of propensity score in observational studies for causal effects. Biometrica 1983, 70:41-55.
177. Rothman K.J., Greenland S. Modern epidemiology 1998, Lippincott Williams & Wilkins, Philadelphia. 2nd edn.
178. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993, 116:117-134.
179. Sadovnick A.D., Eisen K., Ebers G.C., et al. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991, 41:1193-1196.
180. Sadovnick A.D., Ebers G.C., Wilson R.W., et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992, 42:991-994.
181. Sadovnick A.D., Ebers G.C., Dyment D.A., et al. Evidence for genetic basis of multiple sclerosis. Lancet 1996, 347:1728-1730.
182. Sadovnick A.D., Yee I.M.L., Ebers G.C., et al. Multiple sclerosis and birth order: a longitudinal cohort study. Lancet Neurol. 2005, 4:611-617.
183. Sadovnick A.D., Duquette P., Herrera B., et al. A timing-of-birth effect on multiple sclerosis clinical phenotype. Neurology 2007, 69:60-62.
184. Salemi G., Callari G., Gammino M., et al. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol. Scand. 2004, 110:23-26.
185. Sarasoja T., Wikström J., Paltamaa J., et al. Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years. Acta Neurol. Scand. 2004, 110:331-336.
186. Sepcic J., Mesaros E., Materljan E., et al. Nutritional factors and multiple sclerosis in Gorski Kotar, Croatia. Neuroepidemiology 1993, 12:234-240.
187. Serafini B., Roiscarelli B., Franciotta D., et al. Dysregulated Epstein-Barr virus infection in multiple sdclerosis. J. Exp. Med. 2007, 204:2899-2912.
188. Sharief M.K., Thompson E.J. The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann. Neurol. 1991, 29:147-151.
189. Shirodaria P.V., Haire M., Fleming E., et al. Viral antibody titers: Comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch. Neurol. 1987, 44:1237-1241.
190. Sibley W.A., Bamford C.R., Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985, 1:1313-1315.
191. Sinclair H. Polyunsaturated fatty acids in multiple sclerosis. Br. Med. J. 1977, 2:1217.
192. 3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 2005, 175:4119-4126.
193. Staples J., Ponsonby A.L., Lim L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. Br. Med. J. 2010, 340:c1640.
194. Suarez F., Rossignol C., Garabédian M. Interactive effect of estradiol and vitamin D receptor gene polymorphisms as a possible determinant of growth in male and female infants. J. Clin. Endocrinol. Metab. 1998, 83:3563-3568.
195. Sumaya C.V., Myers L.W., Ellison G.W. Epstein-Barr virus antibodies in multiple sclerosis. Arch. Neurol. 1980, 37:94-96.
196. Sumaya C.V., Myers L.W., Ellison G.W., et al. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann. Neurol. 1985, 17:371-377.
197. Sundström P., Nyström L., Forsgren L. Incidence (1988-97) and prevalence (1997) of multiple sclerosis in Västerbotten County in northern Sweden. J. Neurol. Neurosurg. Psychiatry 2003, 74:29-32.
198. Sundström P., Juto G., Wadell G., et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: A prospective study. Neurology 2004, 62:2277-2282.
199. Sundström P., Nyström L., Hallmans G. Smoke exposure increases the risk for multiple sclerosis. Eur. J. Neurol. 2008, 15:579-583.
200. Swank R.L. Multiple sclerosis: a correlation of its incidence with dietary fat. Am. J. Med. Sci. 1950, 220:421-430.
201. Swank R.L. A prospective discussion of past international nutrition catastrophes - indications for the future. Nutrition 1997, 13:344-348.
202. Swank R.L., Dugan B.B. Viewpoint: effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990, 336:37-39.
203. Swank R.L., Grimsgaard A. Multiple sclerosis: the lipid relationship. Am. J. Clin. Nutr. 1988, 48:1387-1393.
204. Swank R.L., Lerstad O., Strom A., et al. Multiple sclerosis in rural Norway: its geographic and occupational incidence in relation to nutrition. N. Engl. J. Med. 1952, 264:721-728.
205. Tavera-Mendoza L.E., White J.H. Cell defenses and the sunshine vitamin. Sci. Am. 2007, 297:62-65. 68-70, 72.
206. Templer D.I., Trent N.H., Spencer D.A., et al. Season of birth in multiple sclerosis. Acta Neurol. Scand. 1992, 85:107-109.
207. Teschke K., Smith J.C., Olshan A.F. Evidence of recall bias in volunteered vs. prompted responses about occupational exposures. Am. J. Ind. Med. 2000, 38:385-388.
208. Thacker E.L., Mirzaei F., Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 2006, 59:499-503.
209. The International Multiple Sclerosis Genetics Consortium (IMSGC) and the Wellcome Trust Case Control Consortium 2 (WTCCC2) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
210. Thorogood M., Hannaford P.C. The influence of oral contraceptives on the risk of multiple sclerosis. Br. J. Obstet. Gynaecol. 1998, 105:1296-1299.
211. Tintore M., Rovira A., Rio J., et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003, 60:27-30.
212. Trapp B.D., Peterson J.P., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
213. Tremlett H., Paty D., Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006, 66:172-177.
214. Tremlett H., Zhao Y., Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult. Scler. 2008, 14:314-324.
215. Trojano M., Pellegrini F., Fuiani A., et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann. Neurol. 2007, 61:300-306.
216. Van der Mei I.A.F., Ponsonby A.-L., Dwyer T., et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Br. Med. J. 2003, 327:316-322.
217. Van der Mei I.A., Ponsonby A.L., Dwyer T., et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 2007, 254:581-590.
218. Vaughan J.H. The Epstein-Barr virus in autoimmunity. Springer Semin. Immunopathol. 1995, 17:203-230.
219. Villard-Macintosh L., Vessey M.P. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception 1993, 47:161-168.
220. Vost A., Wolochow D., Howell D. Incidence of infarcts of the brain in heart diseases. J. Pathol. Bacteriol. 1964, 88:463-470.
221. Vukusic S., Hutchinson M., Hours M., et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predicrtors of post-partum relapse. Brain 2004, 127:1353-1360.
222. Wagner H.J., Hennig H., Jabs W.J., et al. Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis. Viral Immunol. 2000, 13:497-502.
223. Wechsler I.S. Statistics of multiple sclerosis. Arch. Neurol. Psychiatry 1922, 8:59-75.
224. Weinshenker B.G., Bass B., Rice G.P.A., et al. The natural history of multiple sclerosis: a geographically based study: I. clinical course and disability. Brain 1989, 112:133-146.
225. Weinshenker B.G., Bass B., Rice G.P.A., et al. The natural history of multiple sclerosis: a geographically based study: II. predictive value of the early clinical course. Brain 1989, 112:133-146.
226. Willer C.J., Dyment D.A., Risch N.J., et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12877-12882.
227. Willer C.J., Dyment D.A., Sadovnick A.D., et al. Timing of birth and risk of multiple sclerosis: population based study. Br. Med. J. 2005, 330:120-124.
228. Witte J.S., Carlin J.B., Hopper J.L. Likelihood-based approach to estimating twin concordance for dichotomous traits. Genet. Epidemiol. 1999, 16:290-304.
229. Wynn D.R., Rodriguez M., O'Fallon M., et al. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990, 40:780-786.
230. Young L.S., Yao Q.Y., Rooney C.M., et al. New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas. J. Gen. Virol. 1987, 68:2853-2862.
231. Zimber U., Adlinger H.K., Lenoir G.M., et al. Geographical prevalence of two types of Epstein-Barr virus. Virology 1986, 154:56-66.